American Society of Hematology Annual Meeting & Exposition (ASH) | Conference

Many Great Treatments Available for MCL But Questions About Sequencing Remain, Expert Says
December 18, 2022

In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.

Momelotinib May Become ‘No. 1 Choice’ for Second-Line Therapy in Myelofibrosis, Expert Says
December 15, 2022

Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center.

Key Data on Ziftomenib in Relapsed/Refractory AML and Mutant Subgroups
December 14, 2022

Harry P. Erba, MD, PhD, highlights key data on ziftomenib in patients with relapsed/refractory acute myeloid leukemia and its potential as part of a combination regimen.

Low Platelet Count Observed in Treatment Associated With Myelofibrosis
December 14, 2022

According to the phase 3 PERSIST-1 trial and PAC203 trial, thrombocytopenia was associated with myelofibrosis treatment.

Olutasidenib Results in Long-Lasting Responses for IDH1+ Relapsed/Refractory AML
December 14, 2022

Patients with IDH1-mutant relapsed/refractory acute myeloid leukemia achieved a notable complete response rate following treatment with olutasidenib.

BGB-11417± Zanubrutinib Yields Encouraging Results for CLL/SLL
December 14, 2022

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma achieved promising early responses following treatment with BCB-11417 with or without zanubrutinib.

100% MRD Negativity Rate Achieved With Dual-targeting CAR T-cell Therapy in Multiple Myeloma
December 14, 2022

BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100% among patients with multiple myeloma, with all evaluable patients showing MRD negativity to 12 months.

Real-World Quality-of-Life Outcomes of Axi-Cel Treatment in Lymphoma Subtypes Align With Trial Data
December 14, 2022

Real-world data associate axicabtagene ciloleucel with temporarily worse quality of life in patients with diffuse large B cell lymphoma, transformed follicular lymphoma, or follicular lymphoma, which improves within 1-year post-infusion.

Responses to Momelotinib Observed up to 48 Weeks in Anemic Myelofibrosis
December 14, 2022

Patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor experienced durable responses up to 48 weeks with momelotinib.

Addition of Ibrutinib to CRT/ASCT Appears to Improve Outcomes for MCL
December 13, 2022

Treatment with induction and maintenance ibrutinib combined with chemoimmunotherapy and autologous stem cell transplant resulted in statistically significantly improved outcomes in a younger population with mantle cell lymphoma.